Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-2355
- Development stage
- Phase 3
- Lead developer
- Research Foundation for Microbial Diseases of Osaka University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MT-2355 is a pentavalent combination vaccine developed by Mitsubishi Tanabe Pharma Corporation in collaboration with The Research Foundation for Microbial Diseases of Osaka University (Biken) for the prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis, and Haemophilus influenzae type b (Hib) infections, primarily targeting infants. It consists of diphtheria-tetanus-acellular pertussis (DPT), inactivated poliovirus (IPV), and Hib components, designed as a single injection to simplify pediatric immunization schedules in Japan. Phase 3 clinical trials, including confirmatory studies in healthy infants, have been completed, with a marketing authorization application submitted to Japanese regulatory authorities.[3][8][12][20]
- Brand names
- GOBIKGOBIK Aqueous Suspension Syringes
- Other names
- DPT-IPV-Hib vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Adaptive immune receptors specific for poliovirus capsid epitopes
Beyond the preview
Go deeper on MT-2355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-2355.